Literature DB >> 27191675

Boston Type 1 Keratoprosthesis: Visual Outcomes, Device Retention, and Complications.

Kenneth M Goins1, Anna S Kitzmann, Mark A Greiner, Young H Kwon, Wallace L M Alward, Johannes Ledolter, Michael D Wagoner.   

Abstract

PURPOSE: To determine the visual outcomes, device retention, and complications after Boston type 1 keratoprosthesis (KPro-1) device implantation.
METHODS: Comprehensive review of every case of KPro-1 implantation at a tertiary eye care center.
RESULTS: The initial KPro-1 procedure, performed in 75 eyes without a previous keratoprosthesis, was included in the analysis. During the first 6 postoperative months, improvement occurred in the mean preoperative best-corrected visual acuity of 20/1265 to a mean best-obtained postoperative visual acuity of 20/97 (P < 0.001). After a mean follow-up period of 41.4 months (range, 0.8-82.8 months), the final mean best-corrected visual acuity was 20/428. Improved vision was recorded in 43 eyes (57.3%), ambulatory vision (≥20/400) in 47 eyes (62.7%), intermediate functional vision (≥20/80) in 23 eyes (30.7%), and full functional vision (≥20/40) in 11 eyes (14.7%). The initial device was retained in 64 eyes (85.3%), with a Kaplan-Meier retention probability of 96% at 6 months and 82% at 5 years. One or more sight-threatening complications occurred in 51 eyes (68%). These included device extrusion in 11 eyes (14.7%), ulcerative keratitis in 12 eyes (16%), endophthalmitis in 7 eyes (9.3%), sterile vitritis in 3 eyes (4%), retroprosthetic membranes in 25 eyes (33.3%), maculopathy in 26 eyes (34.7%), retinal detachment in 9 eyes (12%), and progressive optic neuropathy in 7 eyes (9.3%).
CONCLUSIONS: Boston KPro-1 implantation is associated with satisfactory visual outcomes and excellent device retention in a majority of cases. However, serious postoperative complications are common and may compromise the final visual result.

Entities:  

Mesh:

Year:  2016        PMID: 27191675     DOI: 10.1097/ICO.0000000000000886

Source DB:  PubMed          Journal:  Cornea        ISSN: 0277-3740            Impact factor:   2.651


  6 in total

1.  COMPARISON OF VISUAL AND ANATOMICAL OUTCOMES OF EYES UNDERGOING TYPE I BOSTON KERATOPROSTHESIS WITH COMBINATION PARS PLANA VITRECTOMY WITH EYES WITHOUT COMBINATION VITRECTOMY.

Authors:  Jennifer I Lim; Lindsay Machen; Andrea Arteaga; Faris I Karas; Robert Hyde; Dingcai Cao; Marcia Niec; Thasarat S Vajaranant; M Soledad Cortina
Journal:  Retina       Date:  2018-09       Impact factor: 4.256

2.  Assessment of Glaucomatous Damage After Boston Keratoprosthesis Implantation Based on Digital Planimetric Quantification of Visual Fields and Optic Nerve Head Imaging.

Authors:  Mohsin H Ali; Mark S Dikopf; Anthony G Finder; Ahmad A Aref; Thasarat Vajaranant; Jose de la Cruz; Maria Soledad Cortina
Journal:  Cornea       Date:  2018-05       Impact factor: 2.651

Review 3.  [Treatment of vascularized high-risk eyes with a Boston keratoprosthesis].

Authors:  F Schaub; M Matthaei; P Enders; S Siebelmann; D Hos; B O Bachmann; C Cursiefen
Journal:  Ophthalmologe       Date:  2021-03-17       Impact factor: 1.059

4.  Results with the Boston Type I keratoprosthesis after Acanthamoeba keratitis.

Authors:  Albert Santos; Luzia Diegues Silva; Luciene Barbosa de Sousa; Denise de Freitas; Lauro Augusto de Oliveira
Journal:  Am J Ophthalmol Case Rep       Date:  2017-03-14

Review 5.  Keratoprosthesis: Current global scenario and a broad Indian perspective.

Authors:  Geetha Iyer; Bhaskar Srinivasan; Shweta Agarwal; Deepti Talele; Ekta Rishi; Pukhraj Rishi; Sripriya Krishnamurthy; Lingam Vijaya; Nirmala Subramanian; Shanmugasundaram Somasundaram
Journal:  Indian J Ophthalmol       Date:  2018-05       Impact factor: 1.848

Review 6.  Boston Type 1 Keratoprosthesis: Updated Perspectives.

Authors:  Manachai Nonpassopon; Muanploy Niparugs; Maria Soledad Cortina
Journal:  Clin Ophthalmol       Date:  2020-04-29
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.